LEO Pharma appoints new Executive Vice President of Global Product Supply
Ballerup, Denmark, August 03, 2022 – LEO Pharma A/S announced today the appointment of Sven Hauptmann as its new Executive Vice President of Global Product Supply, effective August 1, 2022.
Sven joins LEO Pharma with more than 25 years of international experience from Roche where he has held numerous leadership positions within supply chain and manufacturing. He comes with a strong track record delivering world-class results e.g., as Site Lead for Roche’s production site in Ireland, Vice President for Small Molecules Manufacturing and most recently as Senior Vice President for Global Drug Product Manufacturing.
Sven holds a Ph.D. in Chemistry from the Technical University in Darmstadt, Germany and an Executive MBA from Northwestern University – Kellogg School of Management.
“I am delighted and proud to welcome Sven to LEO Pharma. I strongly believe he will bring significant value to our business and drive the transformation agenda in our global product supply as we progress on our ambitious strategy toward 2025,” said Christophe Bourdon, President and CEO of LEO Pharma.
“I am thrilled to join LEO Pharma at such exciting times. LEO Pharma has a long and proud history of innovation and I feel strongly about our mission to advance the standard of care for the benefit of people with skin conditions, their families and society,” said Sven Hauptmann.
Sven Hauptmann succeeds Rhonda Duffy who will be leaving LEO Pharma after more than 29 years with the company. It has been Rhonda’s desire to take time off and spend more time with her family. Rhonda has kindly agreed to ensure a smooth handover in the coming months.
“I would like to thank Rhonda Duffy for her loyalty to LEO Pharma, her drive for constant improvements, and her impressive efforts to bring safe and innovative products to patients. Rhonda’s many years with the company is a testament to her passion for making a difference to patients,” said Christophe Bourdon, President and CEO of LEO Pharma.
Sven Hauptmann's LinkedIn profile
Keywords
Contacts
Karen Støvlbæk Frost
KASFR@leo-pharma.com
VP, Corporate Affairs
Tel: +45 3166 1567
Images
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.23.7.2025 22:30:00 CEST | Pressemeddelelse
ANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S.1 CHE affects approximately one in ten adults worldwide, yet previously, there has been no specific treatment FDA-approved for those living with the disease.2,3 The approval represents an important milestone for LEO Pharma’s expanding presence in the U.S. as it broadens its portfolio of dermatology treatments to address unmet needs.
Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab)14.7.2025 13:00:00 CEST | Pressemeddelelse
Partnership will accelerate and broaden access to treatment for more patients with generalized pustular psoriasis (GPP), a rare and devastating skin condition LEO Pharma’s six decades of dermatology expertise and Boehringer’s global track record in bringing SPEVIGO® to over 40 countries will be combined to ensure continuous patient support Boehringer Ingelheim and LEO Pharma will closely cooperate to ensure a smooth transition of all operations
LEO Pharma Announces Positive 16-Week Interim Results for ADHAND Trial for Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis on the Hands who are Candidates for Systemic Therapy9.7.2025 13:00:00 CEST | Pressemeddelelse
ADHAND is a phase 3b placebo-controlled clinical trial evaluating the efficacy and safety of tralokinumab in adult patients living with moderate-to-severe atopic dermatitis on the hands who are candidates for systemic therapy.1 The 16-week interim results of the ADHAND trial met the primary and all key secondary endpoints, showing statistically significant results compared to placebo. This analysis assessed outcomes up to Week 16, but the trial will continue through Week 32, with final results expected by the end of the year.
LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP)3.6.2025 09:00:00 CEST | Pressemeddelelse
The phase 2a proof-of-concept trial will recruit up to 135 adult patients with mild to severe PPP to investigate the efficacy and safety of delgocitinib cream compared to cream vehicle. Delgocitinib cream has been shown to inhibit the activity of all four JAKs,(1,2) making it a potential therapeutic candidate for treating PPP.
LEO Pharma continues to strengthen strategic leadership in medical dermatology with appointment of Helle Hedegaard Juhl as new EVP of Global People & Corporate Affairs2.6.2025 10:00:00 CEST | Pressemeddelelse
A few weeks ago, LEO Pharma announced the appointment of a new EVP for Global People & Corporate Affairs (GPCA) – Helle Hedegaard Juhl will be joining LEO Pharma on July 1. She joins LEO Pharma, alongside recently appointed EVP for International Operations Frederik Kier, to strengthen the company’s leadership and support the next phase of LEO Pharma's strategic journey and transformation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom